Many poor-risk neuroblastomas and tumours of the Ewing's sarcoma family (ET) recur despite autologous transplants. Recurrence may be due to tumor cells contained in the BM harvests or PBSC harvests. The objectives of this prospective study were to: (1) determine the incidence and degree of tumor cell contamination in paired BM and PBSC harvests; and (2) determine the efficacy of tumor cell purging by immunomagnetic CD34 ؉ cell selection. 198 samples from 11 consecutive patients with neuroblastoma or Ewing's sarcoma were analyzed. We assayed tumor contamination by RT-PCR assay for PGP 9.5, plus immunohistochemistry for neuroblastoma-specific antigens (the latter in neuroblastoma only). None of these patients had tumor cells detected in their BM by clinical histology immediately before BM or PBSC harvests. However, 82% of PBSC and 89% of backup BM harvests were contaminated with tumor by RT-PCR and/or immunocytochemistry assays. Unselected PBSC and BM harvests contained similar quantities of tumor cells (median, ෂ200 000 cells). Cyclophosphamide plus G-CSF mobilization did not affect the incidence or level of contamination in PBSC harvests, as compared to blood obtained before mobilization. Immunomagnetic CD34 ؉ cell selection depleted tumor cells by a median of 3.0 logs for PBSC, and 2.6 logs for BM harvests.
tumors. [3] [4] [5] [6] [7] Nevertheless, only a minority of patients with poor-risk solid cancers treated by high-dose myeloablative radio-chemotherapy are long-term survivors. Relapse posttransplantation can arise from tumor cells in the patient that survive high-dose myeloablative radio-chemotherapy. Gene marking studies have shown that tumor cells which contaminate the hematopoietic graft can also contribute to relapse. 8, 9 Previously, we developed a combination highdose myeloablative radio-chemotherapy regimen for a broad range of childhood cancers. 10 We then developed an immunomagnetic CD34 + cell selection technique to 'reverse purge' autologous bone marrow harvests from pediatric patients. 11 With a prototype Isolex device, the estimated median tumor cell depletion was 2.6 logs for bone marrow harvests. However, the tumor cell content was modelled, not actually measured, in this prior study. The efficacy of tumor cell purging by immunomagnetic CD34 + cell selection of mobilized PBSC harvests from pediatric patients has not been reported.
PBSC harvests have been reported to contain fewer tumor cells and to be less frequently contaminated than bone marrow harvests from patients with breast cancer. 12, 13 However, with improvements in assays by culture, immunocytochemistry and reverse transcriptase PCR (RT-PCR), tumor cells have been detected in peripheral blood and PBSC harvests from pediatric patients. [14] [15] [16] [17] [18] [19] The incidence and levels of contamination of full clinical harvests of marrow vs mobilized blood in the same patients have not been compared in a prospective study.
The objectives of this prospective study were to: (1) determine the incidence and degree of tumor contamination in paired bone marrow harvests and PBSC harvests from patients with poor-risk neuroblastoma and Ewing's sarcoma family of tumors; and (2) determine the efficacy of tumor cell purging by immunomagnetic CD34
+ cell selection of bone marrow harvests vs PBSC harvests. Neuroblastoma and Ewing's sarcoma family tumors were chosen in this study as models for other solid tumors, because highly sensitive immunocytochemistry and RT-PCR assays were available to detect neuroblastoma and Ewing's sarcoma family tumor cells. Cyclophosphamide followed by G-CSF treatment was used for CD34 + cell mobilization in an attempt to maximize the yield of CD34
+ cells and to minimize the frequency of tumor cells in PBSC harvests. We measured blood tumor cell content serially to evaluate whether the incidence and levels of contamination in blood changed during CD34
+ cell mobilization by cyclophosphamide plus G-CSF.
Patients and methods

Patient population
From May 1995 to March 1997, all 11 patients with neuroblastoma or Ewing's sarcomas who enrolled on Johns Hopkins Oncology Center protocol J9511 entered this substudy. J9511 is a study of treatment of children and young adults with poor-risk solid tumors with high dose etoposide, carboplatin and cyclophosphamide, 11 followed by hematopoietic rescue using autologous CD34
+ selected blood stem cells. This study was approved by the Joint Committee for Clinical Investigation of the Johns Hopkins Hospital, and written informed consent was obtained from all patients and/or their parents.
Protocol
Cyclophosphamide (4 g/m 2 i.v. over 1 h) was given on mobilization day 0, and G-CSF (10 g/kg/day subcutaneously) (Amgen, Thousands Oaks, CA, USA) was given from day +2 to the day of leukapheresis for PBSC priming. 13 A single large-volume leukapheresis (2.5 ml/kg/min × 6 h) was performed at the time of optimal CD34 + cell mobilization (day 10-18 after cyclophosphamide administration). Bone marrow harvest was usually performed at the time of second look cancer surgery. For patients with bone marrow metastasis by clinical histology, it was our standard practice to collect PBSC and bone marrow after their marrows were histologically negative for tumor following chemotherapy. Radiation therapy was routinely administered to persistent and prior bulky tumor sites (Ͼ3 cm) before myeloablative chemotherapy: etoposide 800 mg/m 2 /day by continuous infusion on transplant days −6 to −4 (total dose 2400 mg/m 2 ), carboplatin 725 mg/m 2 /day i.v. over 1 h on days −6 to −4 (total dose 2175 mg/m 2 ); and cyclophosphamide 60 mg/kg/day i.v. over 1 h on days −3 and −2 (total dose 120 mg/kg) as described. 11 Both PBSC harvests and bone marrow harvests were positively selected for CD34 + cells. Marrow harvests were held as backup, but not administered to any patient, if the PBSC product post-selection contained у1 million CD34 + cells/kg ideal body weight. If there were Ͻ1 million CD34 + cells/kg in the CD34 + selected PBSC product, the CD34 + selected bone marrow graft was infused for the transplant together with the CD34 + selected PBSC graft.
CD34 + cell selection
Techniques for CD34 + cell selection using the Isolex 300 selection system (Baxter HealthCare, Irvine, CA, USA) have been reported previously. [20] [21] [22] [23] Briefly nucleated cells were incubated with murine anti-CD34 monoclonal antibody (IgG 1 ) and then with with sheep anti-murine IgGcoated paramagnetic microspheres. Unbound CD34 − cells were removed by magnetic washes on the Isolex magnetic cell separator. Incubation with chymopapain was then performed to release microspheres and antibodies from the CD34 + cells. For patient Nos 5, 8, 9 and 10, the PR34+ peptide was used instead of chymopapain to release the microspheres from the CD34 + cells. 24 PR34+ is a solubilized octapeptide which has a strong binding capacity for the primary CD34 antibody. It competes with the CD34 antigen of CD34 + cells for the attachment to the microsphere/antibody complex. 25 
Specimens for tumor assay and stem/progenitor cell assay
Samples of peripheral blood (days 0, 7-20 or until the day of PBSC collection), bone marrow aspirate (day 0 of the PBSC priming cycle), bone marrow harvests (whole unseparated, CD34
+ fraction and CD34 − fraction), and PBSC harvests (whole, CD34
+ fraction and CD34 − fraction) were assayed for occult tumor cell content by RT-PCR ± immunocytochemistry. All of these samples were also assayed for stem/progenitor cell content by colonyforming assay and flow cytometric CD34 + cell count.
Enumeration of blood and marrow CD34 + cells and colony-forming units
The percentage of CD34 + cells was determined by three color flow cytometry using CD45-perCP, CD34(HPCA-2)-PE, and CD71-FITC (Becton Dickinson, Mountain View, CA, USA), analyzed on either a FACScan or FACSCalibur flow cytometer (Becton Dickinson). Anti-HPCA-2 antibody recognizes a chymopapain-resistant epitope of the CD34 molecule.
11 Anti-CD71 antibody was included to identify CD45 − CD71 bright cells in bone marrow samples as nucleated red cells for inclusion in the denominator. CD34 + cells were identified among the low right angle scatter, CD45 low population. 26 Enough events were collected (usually Ͼ50 000) for CD34 + cells to appear as a distinct cluster on displays of right angle scatter vs red fluorescence, or red vs green fluorescence. Colony-forming units granulocyte-macrophage were assayed using standard methylcellulose medium (Stem Cell Technologies, Vancouver, Canada) in triplicate.
Neuroblastoma cell detection by immunocytochemistry
Aseptically collected specimens were placed in sterile tubes containing preservative-free heparin and shipped overnight at room temperature to BIS Laboratories (Reseda, CA, USA). Tubes were coded to preclude investigator bias and preserve patient anonymity. Immunostaining was accomplished using the avidin biotin-alkaline phosphatase technique. Slides were fixed in a paraformaldehyde solution at 4°C for 30 min and washed thoroughly in phosphatebuffered saline. Following fixation, slides were placed on the TechMate immunostainer (Ventana, Tucson, AZ, USA) and incubated with anti-neuroblastoma antibodies (MoAb: 14-2Ga, UJ127.11, 5.1.H11, Anti-Thy-1) at room temperature for 45 min. This was followed by incubations in secondary antibody, blocking solution and then alkaline phosphatase as per protocol. The specimen was then incubated with Ehrlich's hematoxylin counterstain and coverslipped with cytoseal. Neuroblastoma cells were scored if they were both immunologically positive (immunostaining on at least 50% of the cell surface membrane) and morphologically positive (large cells, alone or in clusters, with high nuclear: cytoplasmic ratio, no clumping of chromatin, and prominent nucleoli). To further minimize the possibility of false positive results, detection of at least two tumor cells was required before any specimen was coded as positive. Quantitation of neuroblastoma cells was performed in a blinded fashion by two independent observers. Previous sensitivity and specificity testing showed that as few as one neuroblastoma cell/10 5 mononuclear cells can be detected by immunocytochemistry, and immunostaining of specimens from normal subjects showed no membrane staining.
14, 15 The number of total cells evaluated ranged from 5-30 × 10 4 . The upper 95% confidence limit of the sensitivity of a negative test was therefore approximately one tumor cell/10 5 mononuclear cells. 27 For some CD34 + purified grafts from small patients, the sensitivity of the immunocytochemistry assay was reduced to approximately one tumor cell/3 × 10 4 cells because fewer cells were available for evaluation (to avoid significant consumption of the clinical grafts). The first 24 samples of this study were also tested by tumor colony assay to determine the clonogenicity of the tumor cells detected by immunocytochemistry. The clonogenic assay procedure has been described previously. 17 
Neuroblastoma and Ewing's sarcoma tumor cell detection by multiplex RT-PCR
Preservative-free heparinized specimens described above were collected into tubes containing guanidine isothiocyanate to rapidly denature ribonucleases and extract nucleic acids. Extracts were stored at −20°C, and batch shipped on dry ice to East Carolina University. Tubes were also coded to preclude investigator bias and preserve patient anonymity. The RT-PCR technique has been described. 16, 28 Extracts were processed on cesium chloride gradients to purify total RNA. The resulting RNA was precipitated from ethanol in the presence of glycogen to enhance recovery of RNA, and then resuspended in RNAse-free water and the RNA concentration determined by absorbance at 260 nm. Using an oligo (dT) primer, we created cDNA from the neuron-specific ubiquitin C-terminal hydrolase (PGP 9.5) messenger using up to 5 g total RNA and the SuperScript II preamplification kit (Life Technologies, Gaithersburg, MD, USA). Expression of PGP 9.5 is specific to neuronal tissue. 16, 29 PCR employed a 50 l total reaction volume using 10 × PCR buffer, dNTPs and Taq polymerase, along with 1 l each of the 5′ and 3′ primers and 10 l of the RT reaction mixture as template. With commercially supplied primers (Clontech Laboratories, Palo Alto, CA, USA), glyceraldehyde 3-phosphate dehydrogenase (G3PDH, a housekeeping gene) was co-amplified in the reaction to provide information on sample integrity and tumor-specific signal in the same reaction mixture (Figure 1 ). Following a 60 s pre-soak at 94°C, the PCR reaction was run for 35 cycles according to the protocol supplied with the G3PDH primer set (94°C for 45 s, 60°C for 45 s and 72°C for 2 min, followed by a final 7 min extension at 72°C). A 9 l aliquot of the reaction mixture was subjected to gel electrophoresis in 2% agarose in the presence of ethidium bromide. The resulting bands were photographed under UV trans-illumination. For samples which yielded a weak or equivocal signal for G3PDH, a second PCR was performed on the remainder of the initial RT reaction mixture with reaction conditions as described. Both positive and negative controls were included with each batch of samples run. Previous sensitivity and specificity testing showed that у0.02 g total RNA (as few as one tumor cell in 1 × 10 7 cells) generated a detectable signal, while no signal was generated from 11 blood or marrow samples from normal volunteers. 16 The sensitivity of the RT-PCR assay in this study, however, was limited by the number of cells available for examination (to avoid significant consumption of the clinical grafts). Because only 2-3 × 10 6 mononuclear cells were tested from the clinical grafts, the upper 95% confidence limit of a negative RT-PCR test in the study was therefore ෂ1 in 10 6 nucleated cells.
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Results
Patient characteristics
Eleven patients were studied. Five had neuroblastoma, five had Ewing's sarcomas (three Ewing's sarcoma, two peripheral primitive neuroectodermal tumor), and one had a neuroendocrine tumor. Because the cells from the patient with the neuroendocrine tumor were also positive for PGP 9.5, this patient's results were categorized as belonging to the family of Ewing's sarcomas. Patients' age, risk factors, sites of metastasis, number of cycles of chemotherapy before leukapheresis, and disease status at transplant are shown in Table 1 . Three patients developed progressive disease and did not undergo high-dose myeloablative radiochemotherapy. In all other patients, high-dose myeloablative radio-chemotherapy with autologous stem/progenitor cell rescue was performed after completion of intensive 'induction' or 're-induction' chemotherapy (5-21 cycles lifetime), plus second-look surgery and irradiation to sites of initial tumors and those remaining clinically detectable. Patient Nos 6, 8 and 9 had bony residual disease by MRI and/or bone scans immediately before transplantation. These residual tumors could not be resected without causing severe functional disability and were irradiated before high-dose myeloablative radio-chemotherapy. No other patients had clinical evidence of gross disease at transplant (Table 1) . Tumors from patient Nos 1, 4 and 5 were not N-myc amplified. Dx = diagnosis; NB = neuroblastoma; ESFT = Ewing's sarcoma or peripheral primitive neuroectodermal tumor; NET = neuroendocrine tumor (poorly differentiated); NED = no evidence of disease (by CT and bone scans, urine VMA/HVA, bone marrow morphology); CR = clinical remission; PR = partial response; PD = progressive disease.
CD34 mobilization and CD34 selection efficacy
CD34
+ cells were mobilized with cyclophosphamide (4 g/m 2 ) followed by G-CSF (10 g/kg/day). 13 A median of 2.1 × 10 6 (range 0.13-90 × 10 6 ) CD34 + cells/kg were collected at PBSC harvest, with a median CD34 + cell concentration of 0.15% (range 0.02-3.4%). Immunomagnetic CD34
+ cell selection achieved a median final purity of 92% (49-99%) CD34
+ cells and a median recovery of 55% (range 24-150%) of the initial CD34 + cells (Table 2 ). There was a positive correlation between the number of CD34 + cells/kg in the unprocessed PBSC harvests and the final purity of CD34 + cells (Spearman r = 0.82, P Ͻ 0.01, twosided). For those unprocessed PBSC harvests that contained Ͼ10 6 CD34 + cells/kg (n = 7), the median final purity was 95%. In all six patients transplanted with PBSC grafts alone, purities of the grafts were Ͼ92%. + cell selection achieved a median final purity of 93% (88-97%) CD34
+ cells and a median recovery of 25% (range 11-46%) of the initial CD34
+ cells in the light-density fraction.
Detection of tumor cells in hematopoietic grafts by immunocytochemistry and RT-PCR
We assayed tumor cell contamination in specimens from both bone marrow harvests and PBSC harvests, before and after CD34 + selection. Only three patients had bone marrow metastases by clinical histology at diagnosis (Table 1) , and no patient had detectable tumor in bone marrow by clinical histology immediately before bone marrow harvest or PBSC mobilization. However, tumor cells were detected by immunocytochemistry and/or RT-PCR in nine of the 11 tested (82%) PBSC harvests and 8/9 (89%) backup bone marrow harvests (Table 3) . After CD34 + cell selection, 7/9 (78%) PBSC grafts and 7/8 (88%) bone marrow grafts remained positive for tumor cells by immunocytochemistry and/or RT-PCR. In one bone marrow harvest (patient No. 10) and one PBSC harvest (patient No. 8), contaminating tumor cells were found only after CD34 + cell selection. For cases of neuroblastoma, equal numbers of cells from each sample were evaluated by RT-PCR and by immunocytochemistry. Seven of nine paired (identical) samples of unpurged grafts (Ͼ2 million cells) that were negative for tumor cells by immunocytochemistry were positive by RT-PCR (Table 3) . Similar results were seen for the CD34 − fractions (6/10 pairs were negative by immunocytochemistry but positive by RT-PCR). This suggests that RT-PCR is more sensitive than immunocytochemistry. For the CD34 + fractions, 5/6 samples that were negative by immunocytochemistry were positive by RT-PCR (Table 3 ). Only one sample (patient No. 3) was positive by immunocytochemistry but negative by RT-PCR. Immunocytochemistry was reduced in sensitivity because fewer than the optimal numbers of cells were available for evaluation; this may be part of the reason that some of the cases tested negative by immunocytochemistry but positive by RT-PCR. Tumor colony-forming assays were also performed in the first 24 consecutive samples of the study assayed by immunocytochemistry. All samples (n = 21) that were negative for tumor by immunocytochemistry were negative by colony assay. All samples (n = 3, from patients 1 and 2, with five, 10, and 10 tumor cells per 10 5 mononuclear cells) that were positive by immunocytochemistry were positive by colony assay (one, three, and four colonies per 10 5 mononuclear cells, respectively). This confirmed that the immunocytochemistry assay was highly specific and the detected cells were clonogenic. 32 Reproducibility of RT-PCR results was tested by comparing the results of 17 (seven bone marrow harvests +10 PBSC harvests) paired (coded) whole unseparated transplant graft product vs the corresponding CD34
− fraction. Insufficient sample was obtained from the CD34 − bone marrow product from patient No. 4, and no sample was collected from the CD34 − PBSC product from patient No. 6. There was a 100% agreement between the results from unseparated products vs CD34 − fractions (14 positive pairs and three negative pairs; expected agreement 70%, kappa = 1, P Ͻ 0.001).
Tumor content of bone marrow harvests vs PBSC harvests before and after CD34
+ cell selection
Calculations were done using assumptions on sensitivity of these tumor assays described in the Methods section and in Table 4 (ie one tumor cell in 10 5 or 10 6 nucleated cells for immunocytochemistry or RT-PCR, respectively), together with the following formula:
Tumor cell depletion (logs) = −log 10 (Table 4) .
Tumor cell mobilization
Although all of these patients had tumor-free bone marrow aspirates by clinical histology immediately before PBSC mobilization, both the bone marrow aspirates and blood samples from 7/8 (88%) patients on mobilization day 0 were positive for tumor cells by RT-PCR. Two of five of these bone marrow aspirates and 0/5 of these blood samples were positive by immunocytochemistry. After treatment with cyclophosphamide plus G-CSF for PBSC mobilization, there was a brief reduction in the incidence of cases in which tumor cells were detected in the blood (day 0 vs day 7/8, Fisher's exact, P = 0.001). However, most of the blood samples taken near the peak of CD34 + cell mobilization (range day 11-18) contained tumor cells by RT-PCR ( Figure 2 ). All of these blood samples remained negative by immunocytochemistry, suggesting that the frequency of tumor cells in blood after CD34 + cell mobilization remained between the sensitivities of the two tumor assays (ie ෂ1 in 10 5 -10 6 mononuclear cells). In patient 9, the baseline blood samples were negative for tumor cells by RT-PCR, and all subsequent blood samples remained negative during PBSC mobilization.
Tumor cell contamination in hematopoietic grafts
W Leung et al 976 For neuroblastoma, if immunocytochemistry was positive, the exact tumor cell concentration was used for calculation. If immunocytochemistry was negative and RT-PCR was positive, the tumor cell concentration was assumed to be between 1 in 10 5 cells to 1 in 10 6 cells. If both tests were negative, the tumor cell concentration was assumed to be less than 1 in 10 6 cells. 
Figure 2
Change in incidence of detectable tumor cell contamination in peripheral blood during CD34 + cell mobilization (after treatment with cyclophosphamide followed by G-CSF). Samples of peripheral blood (numbers tested shown on top of the bars, total n = 65 from 11 patients) were collected on day 0, days 7-20 or until the day of PBSC collection (three times a week). The percentage of blood samples that were positive for tumor cells by RT-PCR are shown as a function of time during the mobilization period. All baseline and subsequent blood samples from neuroblastoma patients were negative for tumor cell by ICC.
Tumor progression and patient survival (February 1998)
Of the eight patients who received high-dose myeloablative chemotherapy with autologous stem/progenitor cell transplant, one (patient 4) died of veno-occlusive disease of the liver 1 month after transplant, five developed progressive disease within 8 months, and two showed no clinical evidence of tumor recurrence at Ͼ20 months post-transplant. Two (Nos 2 and 5) of the five patients who developed progressive disease had initial post-transplant cancer recurrence at distant sites. The other three patients (Nos 1, 6 and 8) had initial tumor recurrence at the primary tumor site. Patient No. 6, who had pelvic recurrence at the primary site 3 months after transplant, was treated with external beam radiation therapy and is alive Ͼ26 months after transplant with no evidence of disease. For the two patients (Nos 3 and 9) with no tumor progression for Ͼ20 months posttransplant, all the CD34 + hematopoietic grafts reinfused were positive for tumor cells by RT-PCR only.
Discussion
High-dose myeloablative radio-chemotherapy with autologous stem cell rescue has been used increasingly in the treatment of poor-risk childhood malignancies, but relapse rates remain high. In the present study, 82% of PBSC harvests and 89% of backup bone marrow harvests contained tumor cells, as detected by RT-PCR and/or immunocytochemistry, although all patient marrows were negative for tumor by clinical histology. Other investigators have reported lower incidences of tumor cell contamination in PBSC harvests (0-50%) and bone marrow harvests (30-50%) from pediatric patients with solid tumors. 15, 18, [30] [31] [32] [33] [34] [35] [36] There may be several reasons for this difference. First, the patient populations may be different. Most (82%) of our patients had metastatic disease at diagnosis. Second, the combination of immunocytochemistry and RT-PCR used in this study may be more sensitive than the immunocytochemistry used alone in the earlier studies. In this study many identical unpurged samples that were positive by RT-PCR were negative by immunocytochemistry. Third, some of the positive RT-PCR tests in this study may be false. However, false positive RT-PCR tests appear uncommon: (1) all tests were done with negative controls; (2) the (coded) baseline blood samples from patient 9 were negative for tumor cells by RT-PCR, and all his subsequent (coded) blood samples remained negative during PBSC mobilization; (3) from days 7 to 10 after cyclophosphamide priming, all other patients whose baseline blood samples were positive for tumor cells by RT-PCR had at least one negative RT-PCR test before they reverted to positive (a consistent pattern from coded samples that would not be expected if false positivity were common); and (4) the observed agreement was 100% on results from the 17 paired (coded) analyses of whole unseparated product vs the CD34 − fraction. A prior study showed that analysis of RT-PCR products for PGP 9.5 after 35 cycles by agarose gel electrophoresis alone (without Southern analysis) was uniformly negative on blood and marrow samples from 11 normal volunteers. 16 Some of the negative RT-PCR tests in this study may be false. The sensitivity of our RT-PCR assay for PGP 9.5 is similar to that of the RT-PCR assay for tyrosine hydrolase of neuroblastoma, 34 and that of the RT-PCR assay for t(11;22)(q24;q12) of Ewing's sarcoma. 18 All of these assays are able to detect one tumor cell in 10 5-6 normal nucleated cells. However, the actual sensitivity of these assays in clinical grafts may be limited by the number of cells available for testing, 27 particularly for CD34 + selected grafts from small children. The tumor cell concentrations of all our samples that were positive for tumor cells were in the range of 1 in 10 4-6 nucleated cells. This level of tumor cell contamination is at the limit of detection for our RT-PCR assay, explaining why some of the RT-PCR tests may be falsely negative (eg unselected products of patient Nos 8 and 10). However, tumor cell assays which are more sensitive than those RT-PCR assays are unlikely to be useful to prove complete tumor cell eradication after CD34
+ cell selection, because of the limitation in the number of cells available for testing. It is also impossible to draw broad conclusions about the clinical effect of single immunomagnetic CD34
+ cell selection in this small series with short follow-up. Moreover, even for larger series, the degree of tumor cell contamination before and after CD34
+ cell selection may simply reflect the overall disease status. Nevertheless, the results of gene-marking studies, 8 the positive clonogenicity of the tumor cells detected in this study, and the high incidence of large numbers of tumor cells detected in the PBSC harvests and bone marrow harvests from our patients, support the need for ex vivo purging.
Because most solid cancers lack CD34 expression, isolation of CD34 + cells can be used for 'reverse purging' in a broad range of cancers. 37 In this study, immunomagnetic CD34 + cell selection depleted tumor cells by a median of 3.0 logs for PBSC harvests, and 2.6 logs for bone marrow harvests. This degree of tumor cell depletion is lower than the estimates (median 5.5 and 4 logs, respectively, from the data of the present study) 'modelled' by the formula assuming that tumor cells behaved as CD34
− cells during CD34 + cell selection, and copurified with the normal CD34 − cells. 38 In fact, tumor cell concentrations (right side of the formula) changed little after CD34 + cell selection. The ෂ3 log tumor cell depletion was accounted for mostly by the ෂ3 log decrease in the total number of nucleated cells (left side of the formula) after CD34 + cell selection (Table 2) . Recently, Voigt et al 39 demonstrated binding of CD34 mAbs 12.8 and ICH3 to neuroblastoma cells from many cell lines using flow cytometry. However, no, or only very weak reactivity was observed by using the mAbs 12.8, ICH3, and QBEND10 in fresh clinical specimens. Moreover, after CD34
+ cell selection using the mAb 12.8 from a bone marrow obtained from a neuroblastoma patient, it took 21 days of culture before a neuroblastoma cell colony was observed, whereas many tumor cell colonies were found as early as the 7th day after culture of the the corresponding bone marrow cells before CD34 + cell selection.
This suggests that CD34 + cell selection did not enrich neuroblatoma cells from the fresh clinical graft, but rather depleted the tumor cell concentration. 39 The mAb 9C5, which was used in our CD34
+ cell selection process, was not tested by Voigt et al. We performed monoclonal CD34 antibody (QBEND10) staining of sugical specimens from patients 2 and 3, whose bone marrow harvests and PBSC harvests, respectively, had the lowest degree of tumor cell depletion. Neither tumor expressed CD34 antigen. Overall, the degree of tumor cell depletion in this study for PBSC harvests from pediatric patients compares favorably with the avidin-biotin CD34 + immunoadsorption technique: Handgretinger et al, 35 Ross et al 36 and Laver et al 40 reported a mean log depletion of tumor cells of 1.4, 1.3, and 0.6, respectively. The purging efficacy using neuroblastoma-specific monoclonal antibodies was estimated to be about 2-4 logs in pre-clinical studies, but was only about 0.6 log for clinical grafts in one study. 31, 40 However, the exact purging efficacy by these monoclonal antibodies or by chemical agents in clinical grafts has not been quantified because the frequency of tumor cells after purging is commonly below the limit of sensitivity of the tumor cell assay used. 31, 32 If a single round of immunomagnetic CD34 + cell selection is proven inadequate, repeated CD34
+ cell selection or a combination of positive and negative selection procedures may be performed in the future to further deplete tumor cells from grafts. 41, 42 More effective highdose myeloablative radio-chemotherapy is also likely to be necessary to improve the outcome of these patients. A doseescalation study of cyclophosphamide plus carboplatin and etoposide is on-going at our institution.
We used cyclophosphamide (plus G-CSF) for CD34 + cell mobilization in an attempt to maximize the yield of CD34 + cells and to minimize the numbers of tumor cells in PBSC harvests. 12, 13 There was concern that mobilization might increase the frequency of tumor cells in PBSC harvests. 43 There was no evidence in this study that cyclophosphamide and G-CSF mobilized tumor cells into the peripheral circulation ( Figure 2 ). This is in agreement with the findings in breast cancer patients: there was no difference in the incidences of tumor cell contamination in PBSC harvests after priming with G-CSF alone vs G-CSF after cyclophosphamide. 44 Although PBSC harvests from breast cancer patients appear to contain fewer tumor cells than bone marrow harvests, our study found that PBSC harvests and bone marrow harvests from pediatric patients with solid cancers contained similar total quantities of tumor cells, both before and after CD34 + cell selection. The 0.5-1 log higher concentration of tumor cells in bone marrow harvests was compensated by the 0.5-1 log lower total number of nucleated cells in bone marrow harvests.
We conclude that tumor cells are frequently detectable in marrow and mobilized blood hematopoietic grafts from patients with neuroblastoma and Ewing's sarcomas. Cyclophosphamide plus G-CSF priming did not appear to affect the incidence of tumor cells in PBSC harvests, as compared to blood samples obtained before mobilization. Immunomagnetic CD34
+ selection resulted in high final cell purities and yields, depleting tumor cells by ෂ2.5-3.0 logs, and resulting in relatively few tumor cells in the final CD34 + cell grafts from either source.
